{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:18:29Z","timestamp":1792790309519,"version":"4.5.0"},"posted":{"date-parts":[[2026,9,13]]},"group-title":"Pediatrics","reference-count":49,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T00:00:00Z","timestamp":1789257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ines Mandl Research Foundation","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"https:\/\/ror.org\/02j8zej06","id-type":"ROR","asserted-by":"crossref"}]},{"name":"NIH","award":["R00HL171838"],"award-info":[{"award-number":["R00HL171838"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,9,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Cyclooxygenase (COX) inhibitors have been used to treat hemodynamically significant patent ductus arteriosus (PDA) in preterm infants. If the PDA remains hemodynamically significant after an initial course, additional courses of COX inhibitors or surgical intervention are considered. This systematic review evaluates PDA closure rates and safety after repeated courses of COX inhibitors in preterm infants.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Embase, Medline, and two other databases were searched through April 2026 (pre-registered in PROSPERO [CRD42023454003]). Studies reporting PDA closure rates after two or more courses of COX inhibitors were included. Risk of bias was assessed using Joanna Briggs Institute tools. Meta-analyses with random-effects models were performed to calculate the proportions of PDA closure. Multilevel mixed-effects meta-regression was used to compare closure rates across treatment courses while accounting for within-study correlations.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>\n                    A total of 33 studies were included. The PDA closure rates after the first, second, and third courses of COX inhibitors were 62% (95% confidence interval [CI] 57\u201367%), 46% (95% CI 40\u201352%;\n                    <jats:italic>p<\/jats:italic>\n                    &lt; 0.001 vs the first course), and 38% (95% CI 27\u201351%;\n                    <jats:italic>p<\/jats:italic>\n                    = 0.001 vs the first course), respectively. Lower closure rates with repeated courses were also observed across most subgroups (extremely preterm\/extremely low birth weight, ibuprofen, indomethacin, and intravenous administration), except for the second course of oral administration. Data on adverse events were limited, preventing meta-analysis.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>PDA closure rates after the second and third courses of COX inhibitors were lower than those after the first course in preterm infants. Evidence regarding the safety of repeated courses remains limited.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Impact<\/jats:title>\n                  <jats:list list-type=\"bullet\">\n                    <jats:list-item>\n                      <jats:p>This systematic review is the first study to integrate the PDA closure rates in preterm infants following the second and third courses of COX inhibitor treatment.<\/jats:p>\n                    <\/jats:list-item>\n                    <jats:list-item>\n                      <jats:p>The PDA closure rate after the first course of COX inhibitor treatment was 62%, whereas those after the second and third courses were 46% and 38%, respectively.<\/jats:p>\n                    <\/jats:list-item>\n                    <jats:list-item>\n                      <jats:p>Multilevel meta-regression and pairwise comparisons showed that later COX inhibitor courses yielded significantly lower PDA closure rates than the first.<\/jats:p>\n                    <\/jats:list-item>\n                    <jats:list-item>\n                      <jats:p>Evidence with adverse events after repeated COX inhibitor treatment was limited and required further investigation.<\/jats:p>\n                    <\/jats:list-item>\n                  <\/jats:list>\n                <\/jats:sec>","DOI":"10.64898\/2026.09.09.26360534","type":"posted-content","created":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T21:05:12Z","timestamp":1789333512000},"source":"Crossref","is-referenced-by-count":0,"title":["PDA Closure Rates and Safety after Repeated Courses of Cyclooxygenase Inhibitors in Preterm Infants: A Systematic Review and Meta-Analysis"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4297-727X","authenticated-orcid":false,"given":"Junichi","family":"Saito","sequence":"first","affiliation":[{"name":"Vascular Biology Center, Department of Pediatrics, Medical College of Georgia at Augusta University, Augusta, Georgia, USA"},{"name":"Department of Neonatology, Kanagawa Children\u2019s Medical Center, Yokohama, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5277-9624","authenticated-orcid":false,"given":"Yuka Sano","family":"Wada","sequence":"additional","affiliation":[{"name":"Division of Neonatology, National Center for Child Health and Development, Setagaya, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Yoneda","sequence":"additional","affiliation":[{"name":"Division of Neonatology, National Center for Child Health and Development, Setagaya, Tokyo, Japan"},{"name":"Department of Pediatrics, Teikyo University School of Medicine, Itabashi, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunio","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Health Policy, National Center for Child Health and Development, Setagaya, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiko","family":"Kan","sequence":"additional","affiliation":[{"name":"Departments of Neonatology, Fukuoka Children\u2019s Hospital, Fukuoka, Fukuoka, Japan"},{"name":"Department of Fetal Cardiology, Fukuoka Children\u2019s Hospital, Fukuoka, Fukuoka, Japan"},{"name":"Department of Cardiology, Fukuoka Children\u2019s Hospital, Fukuoka, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Isayama","sequence":"additional","affiliation":[{"name":"Division of Neonatology, National Center for Child Health and Development, Setagaya, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuaki","family":"Toyoshima","sequence":"additional","affiliation":[{"name":"Department of Neonatology, Kanagawa Children\u2019s Medical Center, Yokohama, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"issue":"2","key":"2026091613152395000_2026.09.09.26360534v1.1","doi-asserted-by":"crossref","first-page":"e0212256","DOI":"10.1371\/journal.pone.0212256","article-title":"Natural evolution of ductus arteriosus with noninterventional conservative management in extremely preterm infants born at 23-28 weeks of gestation","volume":"14","year":"2019","journal-title":"PLoS One"},{"key":"2026091613152395000_2026.09.09.26360534v1.2","doi-asserted-by":"crossref","unstructured":"Hamrick SEG , Sallmon H , Rose AT , Porras D , Shelton EL , Reese J , et al. Patent Ductus Arteriosus of the Preterm Infant. Pediatrics. 2020 Nov;146(5).","DOI":"10.1542\/peds.2020-1209"},{"issue":"8","key":"2026091613152395000_2026.09.09.26360534v1.3","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1001\/jamapediatrics.2025.1025","article-title":"Active Treatment vs Expectant Management of Patent Ductus Arteriosus in Preterm Infants: A Meta-Analysis","volume":"179","year":"2025","journal-title":"JAMA Pediatr"},{"key":"2026091613152395000_2026.09.09.26360534v1.4","unstructured":"Laughon MM , Thomas SM , Watterberg KL , Kennedy KA , Keszler M , Ambalavanan N , et al. Expectant Management vs Medication for Patent Ductus Arteriosus in Preterm Infants: The PDA Randomized Clinical Trial. JAMA. 2025 Dec 9."},{"key":"2026091613152395000_2026.09.09.26360534v1.5","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-016-0165-5"},{"key":"2026091613152395000_2026.09.09.26360534v1.6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"issue":"10","key":"2026091613152395000_2026.09.09.26360534v1.7","first-page":"2127","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","year":"2020","journal-title":"JBI Evid Synth"},{"issue":"3","key":"2026091613152395000_2026.09.09.26360534v1.8","first-page":"1","article-title":"Conducting Meta-Analyses in R with the metafor Package","volume":"36","year":"2010","journal-title":"Journal of Statistical Software"},{"key":"2026091613152395000_2026.09.09.26360534v1.9","doi-asserted-by":"publisher","DOI":"10.1136\/ebmental-2019-300117"},{"key":"2026091613152395000_2026.09.09.26360534v1.10","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"2026091613152395000_2026.09.09.26360534v1.11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"2026091613152395000_2026.09.09.26360534v1.12","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-002-0915-y"},{"key":"2026091613152395000_2026.09.09.26360534v1.13","doi-asserted-by":"publisher","DOI":"10.1542\/peds.112.2.345"},{"key":"2026091613152395000_2026.09.09.26360534v1.14","doi-asserted-by":"publisher","DOI":"10.1007\/s00246-007-9166-z"},{"key":"2026091613152395000_2026.09.09.26360534v1.15","doi-asserted-by":"publisher","DOI":"10.1007\/s12519-008-0017-7"},{"key":"2026091613152395000_2026.09.09.26360534v1.16","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2008-2232"},{"key":"2026091613152395000_2026.09.09.26360534v1.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2008.12.101"},{"key":"2026091613152395000_2026.09.09.26360534v1.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2010.10.008"},{"key":"2026091613152395000_2026.09.09.26360534v1.19","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1472-6904-11-8","article-title":"Comparison of renal effects of ibuprofen versus indomethacin during treatment of patent ductus arteriosus in contiguous historical cohorts","volume":"11","year":"2011","journal-title":"BMC Clin Pharmacol"},{"key":"2026091613152395000_2026.09.09.26360534v1.20","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3233\/NPM-2011-51411","article-title":"Second course of oral ibuprofen in closure of patent ductus arteriosus in preterm infants: Is it safe?","volume":"4","year":"2011","journal-title":"Journal of Neonatal-Perinatal Medicine"},{"key":"2026091613152395000_2026.09.09.26360534v1.21","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2431-12-10"},{"key":"2026091613152395000_2026.09.09.26360534v1.22","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2011-300532"},{"issue":"6","key":"2026091613152395000_2026.09.09.26360534v1.23","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.pedneo.2012.08.011","article-title":"Oral ibuprofen versus intravenous indomethacin for closure of patent ductus arteriosus in very low birth weight infants","volume":"53","year":"2012","journal-title":"Pediatr Neonatol"},{"issue":"4","key":"2026091613152395000_2026.09.09.26360534v1.24","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1093\/pch\/17.4.e26","article-title":"Therapeutic strategies, including a high surgical ligation rate, for patent ductus arteriosus closure in extremely premature infants in a North American centre","volume":"17","year":"2012","journal-title":"Paediatr Child Health"},{"issue":"11","key":"2026091613152395000_2026.09.09.26360534v1.25","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1007\/s00431-012-1805-6","article-title":"Repeated courses of ibuprofen are effective in closure of a patent ductus arteriosus","volume":"171","year":"2012","journal-title":"Eur J Pediatr"},{"issue":"9","key":"2026091613152395000_2026.09.09.26360534v1.26","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1055\/s-0032-1332800","article-title":"Effectiveness and safety of indomethacin versus ibuprofen for the treatment of patent ductus arteriosus in preterm infants","volume":"30","year":"2013","journal-title":"Am J Perinatol"},{"key":"2026091613152395000_2026.09.09.26360534v1.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.earlhumdev.2012.09.015"},{"issue":"3","key":"2026091613152395000_2026.09.09.26360534v1.28","first-page":"205","article-title":"Ibuprofen versus indomethacin treatment of patent ductus arteriosus: comparative effectiveness and complications","volume":"20","year":"2014","journal-title":"Hong Kong Med J"},{"key":"2026091613152395000_2026.09.09.26360534v1.29","doi-asserted-by":"publisher","DOI":"10.1159\/000355679"},{"issue":"1","key":"2026091613152395000_2026.09.09.26360534v1.30","first-page":"42","article-title":"The Association between Patent Ductus Arteriosus and Perinatal Infection in A Group of Low Birth Weight Preterm Infants","volume":"24","year":"2014","journal-title":"Iran J Pediatr"},{"issue":"11","key":"2026091613152395000_2026.09.09.26360534v1.31","first-page":"1857","article-title":"May we use ibuprofen as doses against courses in the treatment of patent ductus arteriosus in premature infants?","volume":"29","year":"2016","journal-title":"J Matern Fetal Neonatal Med"},{"key":"2026091613152395000_2026.09.09.26360534v1.32","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-016-2830-7"},{"issue":"1","key":"2026091613152395000_2026.09.09.26360534v1.33","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.pedneo.2015.04.017","article-title":"Repeated Courses of Oral Ibuprofen in Premature Infants with Patent Ductus Arteriosus: Efficacy and Safety","volume":"58","year":"2017","journal-title":"Pediatr Neonatol"},{"key":"2026091613152395000_2026.09.09.26360534v1.34","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.earlhumdev.2019.06.002","article-title":"Patent ductus arteriosus in preterm infants born at 23-24 weeks\u2019 gestation: Should we pay more attention?","volume":"135","year":"2019","journal-title":"Early Hum Dev"},{"issue":"21","key":"2026091613152395000_2026.09.09.26360534v1.35","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1080\/14767058.2018.1470235","article-title":"Efficacy and safety of oral paracetamol versus oral ibuprofen for closure of patent ductus arteriosus in preterm infants: a randomized controlled trial","volume":"32","year":"2019","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"14","key":"2026091613152395000_2026.09.09.26360534v1.36","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1055\/s-0039-1678555","article-title":"Does Postmenstrual Age Affect Medical Patent Ductus Arteriosus Treatment Success in Preterm Infants?","volume":"36","year":"2019","journal-title":"Am J Perinatol"},{"issue":"2","key":"2026091613152395000_2026.09.09.26360534v1.37","doi-asserted-by":"crossref","first-page":"130","DOI":"10.4103\/apc.APC_115_19","article-title":"Comparison of the efficacy and safety of indomethacin, ibuprofen, and paracetamol in the closure of patent ductus arteriosus in preterm neonates - A randomized controlled trial","volume":"13","year":"2020","journal-title":"Ann Pediatr Cardiol"},{"issue":"6","key":"2026091613152395000_2026.09.09.26360534v1.38","first-page":"605","article-title":"Positive tendency toward synchronous use of acetaminophen and ibuprofen in treating patients with patent ductus arteriosus","volume":"48","year":"2020","journal-title":"Turk Kardiyol Dern Ars"},{"issue":"1","key":"2026091613152395000_2026.09.09.26360534v1.39","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1038\/s41598-020-61291-w","article-title":"Plasma B-type natriuretic peptide cannot predict treatment response to ibuprofen in preterm infants with patent ductus arteriosus","volume":"10","year":"2020","journal-title":"Sci Rep"},{"issue":"19","key":"2026091613152395000_2026.09.09.26360534v1.40","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1080\/14767058.2019.1678134","article-title":"Ductal size indexed to weight and body surface area correlates with morbidities in preterm infants","volume":"34","year":"2021","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"3","key":"2026091613152395000_2026.09.09.26360534v1.41","first-page":"548","article-title":"What Should be the First-line Treatment for the Closure of Hemodynamically Significant Patent Ductus Arteriosus in Premature Infants?","volume":"118","year":"2022","journal-title":"Arq Bras Cardiol"},{"key":"2026091613152395000_2026.09.09.26360534v1.42","doi-asserted-by":"crossref","first-page":"106167","DOI":"10.1016\/j.earlhumdev.2024.106167","article-title":"Effectiveness of repeated pharmacological courses for patent ductus arteriosus in preterm infants","volume":"200","year":"2025","journal-title":"Early Hum Dev"},{"key":"2026091613152395000_2026.09.09.26360534v1.43","first-page":"1687361","article-title":"Risk factors for hemodynamically significant patent ductus arteriosus and ibuprofen treatment failure in premature twins: a retrospective case-control study","volume":"12","year":"2025","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"2026091613152395000_2026.09.09.26360534v1.44","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40272-025-00723-4","article-title":"Impact of the Time to Initiation of Indomethacin or Ibuprofen on Patent Ductus Arteriosus Closure Rates","volume":"28","year":"2026","journal-title":"Paediatr Drugs"},{"issue":"8","key":"2026091613152395000_2026.09.09.26360534v1.45","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1001\/jamapediatrics.2020.1447","article-title":"Effect of Nonintervention vs Oral Ibuprofen in Patent Ductus Arteriosus in Preterm Infants: A Randomized Clinical Trial","volume":"174","year":"2020","journal-title":"JAMA Pediatr"},{"key":"2026091613152395000_2026.09.09.26360534v1.46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200009073431001"},{"key":"2026091613152395000_2026.09.09.26360534v1.47","doi-asserted-by":"crossref","first-page":"104418","DOI":"10.1016\/j.phrs.2019.104418","article-title":"Efficacy and safety of pharmacological treatments for patent ductus arteriosus closure: A systematic review and network meta-analysis of clinical trials and observational studies","volume":"148","year":"2019","journal-title":"Pharmacol Res"},{"issue":"1","key":"2026091613152395000_2026.09.09.26360534v1.48","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/bcp.12752","article-title":"Evaluation of changes in oral drug absorption in preterm and term neonates for Biopharmaceutics Classification System (BCS) class I and II compounds","volume":"81","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"2026091613152395000_2026.09.09.26360534v1.49","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.09.09.26360534","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:15:36Z","timestamp":1789589736000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.64898\/2026.09.09.26360534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,13]]},"references-count":49,"URL":"https:\/\/doi.org\/10.64898\/2026.09.09.26360534","relation":{},"subject":[],"published":{"date-parts":[[2026,9,13]]},"subtype":"preprint"}}